Macrophage inflammatory protein 1-alpha (MIP-1α) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells
- 1 May 2003
- journal article
- Published by American Society of Hematology in Blood
- Vol. 101 (9) , 3568-3573
- https://doi.org/10.1182/blood-2002-08-2383
Abstract
Recently, it has been demonstrated that macrophage inflammatory protein 1- alpha (MIP-1α) is crucially involved in the development of osteolytic bone lesions in multiple myeloma (MM). The current study was designed to determine the direct effects of MIP-1α on MM cells. Thus, we were able to demonstrate that MIP-1α acts as a potent growth, survival, and chemotactic factor in MM cells. MIP-1α–induced signaling involved activation of the AKT/protein kinase B (PKB) and the mitogen-activated protein kinase (MAPK) pathway. In addition, inhibition of AKT activation by phosphatidylinositol 3- kinase (PI3-K) inhibitors did not influence MAPK activation, suggesting that there is no cross talk between MIP-1α–dependent activation of the PI3-K/AKT and extracellular-regulated kinase (ERK) pathway. Our data suggest that besides its role in development of osteolytic bone destruction, MIP-1α also directly affects cell signaling pathways mediating growth, survival, and migration in MM cells and provide evidence that MIP-1α might play a pivotal role in the pathogenesis of MM.Keywords
This publication has 23 references indexed in Scilit:
- Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone diseaseJournal of Clinical Investigation, 2001
- Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myelomaOncogene, 2001
- Macrophage inflammatory protein-1α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor κB ligandBlood, 2001
- Through the looking glass: the diverse in vivo activities of chemokinesJournal of Clinical Investigation, 1999
- Chimaeric anti‐interleukin 6 monoclonal antibodies in the treatment of advanced multiple myeloma: a phase I dose‐escalating studyBritish Journal of Haematology, 1998
- An activated mutant of R-Ras inhibits cell death caused by cytokine deprivation in BaF3 cells in the presence of IGF-IOncogene, 1997
- Dexamethasone induces apoptosis of multiple myeloma cells in a JNK/SAP kinase independent mechanismOncogene, 1997
- Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myelomaProceedings of the National Academy of Sciences, 1996
- Therapeutic strategies for inhibition of interleukin-6 mediated multiple myeloma cell growthLeukemia Research, 1996
- Interleukin 6 is essential for in vivo development of B lineage neoplasms.The Journal of Experimental Medicine, 1995